SSA
ELVN icon

Schonfeld Strategic Advisors’s Enliven Therapeutics ELVN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.84M Sell
55,884
-162,983
-74% -$6.92M 0.01% 889
2026
Q1 		$8.58M Buy
+218,867
New +$6.06M 0.06% 335

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Schonfeld Strategic Advisors's ELVN Position: Q2 2026 in Review

Schonfeld Strategic Advisors reduced its Enliven Therapeutics (ELVN) stake by 74% in Q2 2026, selling an estimated $6.92M and leaving 55,884 shares worth $2.84M. The position accounts for 0.01% of the portfolio, ranked #889.

Schonfeld Strategic Advisors first reported a position in ELVN in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.58M in Q1 2026. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Schonfeld Strategic Advisors held 55,884 shares of Enliven Therapeutics worth $2.84M as of Q2 2026.
  • Schonfeld Strategic Advisors sold 162,983 Enliven Therapeutics shares in Q2 2026, an estimated $6.92M.
  • Enliven Therapeutics made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #889 holding.
  • Schonfeld Strategic Advisors first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Schonfeld Strategic Advisors's Enliven Therapeutics position peaked at $8.58M in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.